EQUITY RESEARCH - RESULTS FLASH



THAILAND / HEALTH CARE SERVICES

CHG TB



THB4.00

THB2.84

+40.8%

+17.2%

3Q23 results at first glance

3Q23 core profit jumped by 58% q-q to THB326m, beating our estimate

Highlights

- CHG reported a core profit of THB326m in 3Q23 (+26% y-y, +58% qq), beating our estimate by 7% and the Bloomberg consensus estimate by 11% mainly due to higher-than-expected cash patient revenue and an EBITDA margin of 26% (vs our forecast of 24%).
- Revenue grew 16% q-q and 3% y-y in 3Q23, beating our estimate. Non-Covid patient revenue (cash patient and NHSO patient revenue) grew by 23% q-q and exceeded the pre-Covid level by 53%. Meanwhile, SSO revenue grew by 2% q-q and exceeded pre-Covid by 32% due to the higher payment rate (THB1,808/head/year from THB1,640 effective May-23).
- Depreciation and interest expenses increased by 12% q-q in the quarter due to CHG Mae Sot and CHG Medical Center, which recently opened.
- The 3Q23 EBITDA margin improved to 26% (vs 21% in 2Q23) thanks to strong cash patient revenue.
- 9M23 core profit of THB772m accounted for 65% of our 2023 forecast of THB1.2b.

Outlook

We expect the strong earnings momentum to continue in 4Q23. The loss from CHG Mae Sot should decrease as its revenue stream improves. In addition, CHG should book an additional gain of cTHB40-60m from chronic disease treatments in 4Q23 since the actual receipt is likely to exceed the accrued amount.

KEY STOCK DATA

YE Dec (THB m)	2022	2023E	2024E	2025E
Revenue	10,103	7,606	8,205	8,748
Net profit	2,778	1,186	1,371	1,548
EPS (THB)	0.25	0.11	0.12	0.14
vs Consensus (%)	-	11.1	5.3	12.0
EBITDA	3,947	1,964	2,218	2,467
Recurring net profit	2,778	1,186	1,371	1,548
Core EPS (THB)	0.25	0.11	0.12	0.14
EPS growth (%)	(33.9)	(57.3)	15.5	12.9
Core P/E (x)	11.2	26.3	22.8	20.2
Dividend yield (%)	5.6	2.3	2.6	3.0
EV/EBITDA (x)	7.7	15.1	13.1	11.5
Price/book (x)	4.2	4.1	3.8	3.5
Net debt/Equity (%)	(14.4)	(23.9)	(29.1)	(35.8)
ROE (%)	36.8	15.7	17.4	18.1

TARGET PRICE

UP/DOWNSIDE

TP vs CONSENSUS

CLOSE



Share price performance	1 Month	3 Month	12 Month			
Absolute (%)	(9.0)	(5.3)	(19.3)			
Relative to country (%)	(4.7)	4.9	(5.5)			
Mkt cap (USD m)			866			
3m avg. daily turnover (USD m)			3.3			
Free float (%)			43			
Major shareholder	Kannikar Plussind (18%					
12m high/low (THB)	n high/low (THB) 4.04/2.					
Issued shares (m)			11,000.00			

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: CHG - 3Q23 results summary

	3Q22	4Q22	1Q23	2Q23	3Q23	Cha	nge	2023E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(y-y %)				
Revenue	2,026	1,721	1,716	1,799	2,093	16	3	7,606	(25)
Cost of sales (Incl. depreciation)	(1,480)	(1,229)	(1,276)	(1,380)	(1,486)	8	0	(5,431)	(8)
Gross profit	546	492	440	418	607	45	11	2,175	(48)
SG&A	(253)	(254)	(200)	(222)	(246)	11	(3)	(936)	0
Operating profit	293	238	240	196	361	84	23	1,240	(62)
Other operating income	74	96	73	70	77	10	4	314	3
Interest income	0	2	1	3	1			4	(28)
Equity income	0	(1)	(3)	(2)	(5)				0
EBIT	367	334	309	267	434	63	18	1,558	(56)
Interest expense	(4)	(6)	(4)	(5)	(7)	44	74	(30)	82
EBT	364	328	305	262	427	63	17	1,528	(57)
Income tax	(97)	(40)	(60)	(56)	(90)	63	(7)	(306)	(57)
Minority interests	(8)	(3)	(5)	(0)	(11)		32	(36)	n/a
Core profit	258	285	240	206	326	58	26	1,186	(57)
Extraordinaries									
Net income	258	285	240	206	326	58	26	1,186	(57)
Core EPS (THB)	0.02	0.03	0.02	0.02	0.03	58	26	0.11	(57)
No of share (m)	11,000	11,000	11,000	11,000	11,000	0	0	11,000	0
No of share (III)	11,000	11,000	11,000	11,000	11,000	Ü	Ü	11,000	Ü
Cost (Excl. depreciation)	(1,379)	(1,135)	(1,177)	(1,276)	(1,370)	7	(1)	(5,020)	(9)
Depreciation & amortization	(101)	(93)	(99)	(104)	(117)	12	16	(411)	8
EBITDA	468	427	411	370	554	50	18	1,964	(50)
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(ppt)
Gross margin	27	29	26	23	29	6	2	29	(13)
SG&A/Revenue	12	15	12	12	12	(1)	(1)	12	3
EBITDA margin	23	25	24	21	26	6	3	26	(13)
Net profit margin	13	17	14	11	16	4	3	16	(12)
Operating stats	(y-y %)								
SSO revenue	54	(7)	19	23	8				
SSO registered members ('000)	513	520	525	528	-				
SSO revenue per head	38	(17)	10	17					
Cash-OPD revenue	24	(38)	(41)	(20)	(6)				
Cash-OPD visit number	13	(5)	(19)	(7)	(-)				
Cash-OPD revenue per head	10	(34)	(26)	(13)					
Cash-IPD revenue	14	29	(5)	5	24				
		_~	(~)	•					
Cash-IPD admission number	56	30	9	30					

Sources: CHG; FSSIA estimates

Financial Statements

Chularat Hospital

Profit and Loss (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Revenue	11,742	10,103	7,606	8,205	8,748
Cost of goods sold	(5,882)	(5,908)	(5,431)	(5,777)	(6,068)
Gross profit	5,860	4,195	2,175	2,428	2,680
Other operating income	257	305	314	323	333
Operating costs	(821)	(935)	(936)	(976)	(1,015)
Operating EBITDA	5,647	3,947	1,964	2,218	2,467
Depreciation	(351)	(382)	(411)	(444)	(469)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	5,296	3,565	1,553	1,774	1,998
Net financing costs	(19)	(10)	(25)	(14)	(12)
Associates	0	(1)	0	0	0
Recurring non-operating income	0	(1)	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	5,276	3,554	1,528	1,761	1,986
Tax	(1,009)	(703)	(306)	(352)	(397)
Profit after tax	4,267	2,850	1,222	1,409	1,589
Minority interests	(63)	(72)	(36)	(38)	(41)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	4,204	2,778	1,186	1,371	1,548
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	4,204	2,778	1,186	1,371	1,548
Per share (THB)					
Recurring EPS *	0.38	0.25	0.11	0.12	0.14
Reported EPS	0.38	0.25	0.11	0.12	0.14
DPS	0.20	0.16	0.06	0.07	0.08
Diluted shares (used to calculate per share data)	11,000	11,000	11,000	11,000	11,000
Growth					
Revenue (%)	116.1	(14.0)	(24.7)	7.9	6.6
Operating EBITDA (%)	287.4	(30.1)	(50.2)	12.9	11.2
Operating EBIT (%)	379.7	(32.7)	(56.4)	14.2	12.6
Recurring EPS (%)	379.6	(33.9)	(57.3)	15.5	12.9
Reported EPS (%)	379.6	(33.9)	(57.3)	15.5	12.9
Operating performance					
Gross margin inc. depreciation (%)	49.9	41.5	28.6	29.6	30.6
Gross margin exc. depreciation (%)	52.9	45.3	34.0	35.0	36.0
Operating EBITDA margin (%)	48.1	39.1	25.8	27.0	28.2
Operating EBIT margin (%)	45.1	35.3	20.4	21.6	22.8
Net margin (%)	35.8	27.5	15.6	16.7	17.7
Effective tax rate (%)	19.1	19.8	20.0	20.0	20.0
Dividend payout on recurring profit (%)	52.3	63.3	60.0	60.0	60.0
Interest cover (X)	271.9	349.5	61.3	129.4	161.2
Inventory days	15.6	18.5	18.4	17.0	17.1
Debtor days	17.1	24.8	38.1	38.9	38.2
Creditor days	46.6	55.9	59.0	54.5	54.9
Operating ROIC (%)	83.2	47.1	19.8	23.9	27.1
ROIC (%)	80.4	45.1	18.8	22.6	25.6
ROE (%)	72.5	36.8	15.7	17.4	18.1
ROA (%)	51.1	27.4	12.5	14.2	14.8
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2021	2022	2023E	2024E	2025E
Cash patient revenue	4,222	5,160	4,859	5,255	5,684
SSO patient revenue	1,928	2,149	2,324	2,513	2,615
NHSO patient revenue	5,592	2,794	424	436	449

Sources: Chularat Hospital; FSSIA estimates

Financial Statements

Chularat Hospital

Cash Flow (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Recurring net profit	4,204	2,778	1,186	1,371	1,548
Depreciation	351	382	411	444	469
Associates & minorities	-	-	-	-	
Other non-cash items	50	117	36 914	38	4′
Change in working capital Cash flow from operations	(540) 4,065	(696) 2,582	2,548	(91) 1,762	(10 2,04 8
Capex - maintenance	(539)	(777)	(600)	(410)	(350
Capex - new investment	(339)	(777)	(000)	(410)	(330
let acquisitions & disposals	0	(142)	0	0	(
Other investments (net)	-	(1-12)	-	-	`
Cash flow from investing	(539)	(919)	(600)	(410)	(350
Dividends paid	(660)	(2,805)	(1,155)	(712)	(823
Equity finance	0	0	0	0	(020
Debt finance	(665)	356	(470)	0	
Other financing cash flows	40	(3)	(36)	(38)	(41
Cash flow from financing	(1,284)	(2,452)	(1,661)	(750)	(8 6 3
Non-recurring cash flows	-	-	-	-	
Other adjustments	0	0	0	0	
Net other adjustments	0	0	0	0	(
Movement in cash	2,242	(789)	287	602	83
Free cash flow to firm (FCFF)	3,547.55	1,679.02	1,977.55	1,370.49	1,716.8
Free cash flow to equity (FCFE)	2,901.73	2,016.07	1,441.63	1,314.16	1,657.50
Per share (THB)					
FCFF per share	0.32	0.15	0.18	0.12	0.16
FCFE per share	0.26	0.18	0.13	0.12	0.1
Recurring cash flow per share	0.42	0.30	0.15	0.17	0.19
Salance Sheet (THB m) Year Ending Dec	2021	2022	2023E	2024E	2025E
Tangible fixed assets (gross)	7,129	7,867	8,467	8,878	9,228
Less: Accumulated depreciation	(2,661)	(2,987)	(3,398)	(3,842)	(4,311
Tangible fixed assets (net)	4,468	4,880	5,069	5,035	4,910
ntangible fixed assets (net)	47	47	47	47	4
Long-term financial assets	-	- 110	- 440	- 110	4.4
nvest. in associates & subsidiaries	0 2,790	142	142	142	142
Cash & equivalents VC receivable	2,790 616	2,001 757	2,287 833	2,890 915	3,725 915
nventories	295	265	241	256	268
Other current assets	2,196	2,036	878	947	1,009
Current assets	5,897	5,058	4,239	5,007	5,917
Other assets	137	152	152	152	15:
Total assets	10,550	10,280	9,649	10,384	11,17
Common equity	7,569	7,523	7,555	8,214	8,93
Minorities etc.	272	341	341	341	34
Fotal shareholders' equity	7,841	7,864	7,895	8,554	9,28
ong term debt	480	470	0	0	
Other long-term liabilities	137	233	233	233	23
ong-term liabilities	617	704	233	233	23
A/C payable	842	851	773	821	86
Short term debt	34	400	400	400	40
Other current liabilities	1,215	462	348	375	40
Current liabilities	2,092	1,712	1,520	1,596	1,66
Total liabilities and shareholders' equity	10,550	10,280	9,649	10,384	11,17
Net working capital	1,050	1,745	831	922	93
nvested capital	5,702	6,967	6,241	6,298	6,18
Includes convertibles and preferred stock which is be	eing treated as debt				
Per share (THB)					
Book value per share	0.69	0.68	0.69	0.75	0.8
angible book value per share	0.68	0.68	0.68	0.74	0.8
inancial strength					
Net debt/equity (%)	(29.0)	(14.4)	(23.9)	(29.1)	(35.8
Net debt/total assets (%)	(21.6)	(11.0)	(19.6)	(24.0)	(29.8
Current ratio (x)	2.8	3.0	2.8	3.1	3.
CF interest cover (x)	150.0	198.7	57.9	96.9	134.
/aluation	2021	2022	2023E	2024E	2025
Recurring P/E (x) *	7.4 10.5	11.2	26.3 27.4	22.8	20.
Recurring P/E @ target price (x) *	10.5	15.8	37.1	32.1	28.
Reported P/E (x)	7.4	11.2	26.3	22.8	20.
Dividend yield (%)	7.0	5.6	2.3	2.6	3
Price/book (x)	4.1	4.2	4.1	3.8	3
Price/tangible book (x)	4.2	4.2	4.2	3.8	3
EV/EBITDA (x) **	5.2	7.7	15.1	13.1	11
EV/EBITDA @ target price (x) **	7.4	10.9	21.6	18.9	16
V/invested capital (x)	5.1	4.4	4.8	4.6	4

Sources: Chularat Hospital; FSSIA estimates

Chularat Hospital PCL (CHG TB)



Exhibit 2: FSSIA ESG score implication

38.25 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Dome	stic ratings					Glob	al ratings			Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71			-	4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Υ	Υ	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25			-	4.00	5.00		High	55.35	-		59.57	21.00	2.34	50.24
PR9	54.08		Υ	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00			-	4.00	4.00	Certified			-					
RAM	11.75			-	3.00			High							
THG	18.75			-	5.00	5.00		High							
VIBHA	20.88			-	4.00	3.00	Declared	High					17.00		

 $Sources: \underline{\textbf{SETTRADE.com}}; \ \textbf{FSSIA's compilation}$

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	_	_	2.21	2.34
BESG environmental pillar score	_	_	4.04	4.18
BESG social pillar score	_	_	0.74	0.79
BESG governance pillar score	_	_	4.19	4.49
ESG disclosure score	36.82	36.82	41.54	50.24
Environmental disclosure score	16.49	16.49	17.67	32.92
Social disclosure score	12.70	12.70	19.41	30.29
Governance disclosure score	81.10	81.10	87.36	87.36
Environmental				
Emissions reduction initiatives	Yes	Yes	Yes	Yes
Climate change policy	No	No	Yes	Yes
Climate change opportunities discussed	No	No	No	No
Risks of climate change discussed	No	No	No	No
GHG scope 1	0	0	0	0
GHG scope 2 location-based	4	4	4	4
GHG Scope 3	1	1	1	1
Carbon per unit of production	_	_	_	_
Biodiversity policy	No	No	No	No
Energy efficiency policy	Yes	Yes	Yes	Yes
Total energy consumption	_	_	_	_
Renewable energy use	_	_	_	_
Electricity used	4	4	4	7
Fuel used - natural gas	_	_	_	_

 $Sources: Bloomberg; FSSIA's \ compilation$

Exhibit 5: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No
Waste reduction policy	Yes	Yes	Yes	Yes
Hazardous waste	0	0	0	(
Total waste	1	1	1	•
Waste recycled	0	0	0	(
Waste sent to landfills	_	_	_	_
Environmental supply chain management	No	No	No	No
Water policy	No	No	Yes	Yes
Water consumption	89	73	80	70
Social				
Human rights policy	Yes	Yes	Yes	Ye
Policy against child labor	Yes	Yes	Yes	Ye
Quality assurance and recall policy	No	No	No	N
Consumer data protection policy	Yes	Yes	Yes	Ye
Equal opportunity policy	Yes	Yes	Yes	Ye
Gender pay gap breakout	No	No	No	N
Pct women in workforce	_	_	84	8
Pct disabled in workforce	_	_	_	-
Business ethics policy	Yes	Yes	Yes	Ye
Anti-bribery ethics policy	Yes	Yes	Yes	Ye
Health and safety policy	Yes	Yes	Yes	Ye
Lost time incident rate - employees	_	_	_	
Total recordable incident rate - employees	_	_	_	_
Training policy	Yes	Yes	Yes	Ye
Fair remuneration policy	No	No	No	N
Number of employees – CSR	3,612	3,616	3,871	4,52
Employee turnover pct	_	_	20	2
Total hours spent by firm - employee training	_	_	32,904	85,88
Social supply chain management	No	No	No	N
Governance				
Board size	12	12	12	1
No. of independent directors (ID)	4	4	4	
No. of women on board	2	2	2	
No. of non-executive directors on board	_ 11	11	11	1
Company conducts board evaluations	Yes	Yes	Yes	Ye
No. of board meetings for the year	6	7	7	
Board meeting attendance pct	100	100	, 95	10
Board duration (years)	3	3	3	10
Director share ownership guidelines	No	No	No	N
Age of the youngest director	60	62	63	5
Age of the oldest director	77	78	79	8
No. of executives / company managers	6	6	6	
No. of female executives	2	2	2	
	No	No	No	N
Executive share ownership guidelines				
Size of audit committee	3	3	3	
No. of ID on audit committee	3	3	3	
Audit committee meetings	5	5	5	4.0
Audit meeting attendance %	100	100	100	10
Size of compensation committee	5	5	5	
No. of ID on compensation committee	4	4	4	
No. of compensation committee meetings	2	2	2	
Compensation meeting attendance %	100	100	83	10
Size of nomination committee	5	5	5	
No. of nomination committee meetings	2	2	2	
Nomination meeting attendance %	100	100	83	10
Sustainability governance				
Verification type	No	No	No	N

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodology				Rating						
The Dow Jones Sustainability ndices (<u>DJSI</u>) By S&P Global	process based from the annu- Only the top-ra inclusion.	I on the comp al S&P Globa anked compar	ansparent, rules-based anies' Total Sustainabili I Corporate Sustainabilit nies within each industry	ity Scores resulting y Assessment (CSA). y are selected for	Sustainability ESG Score o scoring comp selected from	Assessment f less than 45 any are disq the Eligible		I. Companie Global ESG nstituents of	s with an S&P Score of the hi the DJSI indic	ighest ces are	
Sustainability nvestment List (THSI) by The Stock Exchange of Thailand SET)	managing bus Candidates m 1) no irregular float of >150 s up capital. Sor 70%; 2) indep wrongdoing re	iness with trai ust pass the p trading of the hareholders, a me key disqua endent director lated to CG, s	ty in Environmental and insparency in Governance oreemptive criteria, with in the board members and en and combined holding in alifying criteria include: 1 ors and free float violation social & environmental in rnings in red for > 3 year	ce, updated annually. two crucial conditions: tecutives; and 2) free nust be >15% of paid- 1) CG score of below in; 3) executives' impacts; 4) equity in	minimum of 5 during the ass nature of the SETTHSI Indicapitalization >0.5% of paid Index is a ma	0% for each sessment year levant induserelevant ind	Iusion, verified indicator, unles ar. The scoring stry and materied from the TH JSD150b); 2) from at least 9 out ation-weighted number of stock	ss the compa will be fairly ality. SI companie ee float >20° of 12 month index, cap 5	ny is a part of weighted agai s whose 1) ma %; and 3) liqui s. The SETTH	DJSI inst the arket dity ISI	
CG Score by Thai institute of Directors association Thai IOD)	annually by the	e Thai IOD, w i). The results	in sustainable developn ith support from the Sto are from the perspectiv	ck Exchange of	Good (80-89) and not rated equitable trea	, 3 for Good for scores be tment of sha (25%); 4) dis	egories: 5 for E (70-79), 2 for F elow 50. Weigh reholders (weig closure & trans	air (60-69), 1 tings include ght 25% com	for Pass (60- : 1) the rights; bined); 3) the	·69), ; 2) an role o	
AGM level By Thai nvestors Association TIA) with support from he SEC	treatment are transparent ar out of five the assessment of the meeting dradvance circulat rights can be exe transparency and	incorporated in discription and sufficiently CG compone riteria cover A late (45%), and for of sufficient dercised. The second verifiability; and	nich shareholders' rights into business operations disclosed. All form impo ints to be evaluated annu. GM procedures before to dafter the meeting (10% information for voting; and 2 cond assesses 1) the ease of d3) openness for Q&A. The tain discussion issues, reso	and information is utant elements of two ually. The the meeting (45%), at a condition of the first assesses 1); facilitating how voting of attending meetings; 2) to third involves the			nto four catego air (80-89), and				
Thai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishment policies. The C (Companies dec Declaration of In Certification, incl	of key control Certification is iding to become tent to kick off a uding risk asses mployees, estate	necklist include corruptions, and the monitoring and good for three years. a CAC certified member stands and the additional to substant, in place of policy and instance of the stakeholders.)	and developing of art by submitting a mit the CAC Checklist for ad control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Counc approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.					uncil	
Morningstar Sustainalytics							ng score is the he higher ESG			he	
		pany feedback,	er media, NGO reports/webs ESG controversies, issuer t ws.		NEGL 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+		
ESG Book	positioned to on the principle on helps explain to	outperform over f financial mat future risk-adj g features with	istainable companies that it is a tributed in the long term. The meteriality including information in the long term is a tributed in higher materiality and it is a tributed in the long term is a tributed in the long term. The long term is a tributed in the long term is a tributed in the long term.	ethodology considers ation that significantly eriality is applied by	0 , 0						
<u>MSCI</u>			easure a company's ma d laggards according to t							ogy to	
	AAA	8.571-10.000	Leader:	leading its industry in n	nanaging the most	significant ES	G risks and oppor	tunities			
	AA	7.143-8.570		- ,		-	• • •				
	A	5.714-7.142	A	a mixed or unexception	nal track record of	managing the r	nost significant E	SG risks and o	pportunities relat	tive to	
	BBB BB	4.286-5.713 2.857-4.285	Average:	industry peers			-				
	В	1.429-2.856									
	ccc	0.000-1.428	Laggard:	lagging its industry bas	ed on its high exp	osure and failu	e to manage sign	ificant ESG ris	ks		
Moody's ESG olutions	Moody's asses	sses the degree	ee to which companies t egrating ESG factors int shareholders over the r	o its business model an							
Refinitiv ESG rating	based on publ	icly available	nd objectively measure and auditable data. The a publicly. (Score ratings a	score ranges from 0 to	100 on relative	ESG perforn	nance and insu	fficient degre			
S&P Global			e is a relative score mean the same industry clas				ent of ESG risks	s, opportuniti	es, and impac	ts	
Bloomberg	ESG Score			nberg's view of ESG fina	ancial materialit	y. The score	is a weighted g	jeneralized n	nean (power m	nean)	
Bloomberg	ESG Disclosu	score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best. ESG Disclosure Score Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of									

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
21-Jan-2021 26-Apr-2021 20-May-2021	BUY BUY BUY	3.50 3.90 4.00	05-Aug-2021 09-Feb-2023 03-Aug-2023	BUY BUY BUY	4.70 4.40 3.90	03-Nov-2023	BUY	4.00

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Chularat Hospital	CHG TB	THB 2.84	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic concerns; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 14-Nov-2023 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.